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Abstract
The drugs cyclosporine A (CsA) and tacrolimus (FK506) revolutionized organ transplantation. Both
compounds are still widely used in the clinic as well as for basic research, even though they have
dramatic side effects and modulate other pathways than calcineurin-NFATc, too. To answer the
major open question - whether the adverse side effects are secondary to the actions of the drugs
on the calcineurin-NFATc pathway - alternative inhibitors were developed. Ideal inhibitors should
discriminate between the inhibition of (i) calcineurin and peptidyl-prolyl cis-trans  isomerases
(PPIases; the matchmaker proteins of CsA and FK506), (ii) calcineurin and the other Ser/Thr
protein phosphatases, and (iii) NFATc and other transcription factors. In this review we summarize
the current knowledge about novel inhibitors, synthesized or identified in the last decades, and
focus on their mode of action, specificity, and biological effects.
Background
The calcium-dependent serine/threonine (Ser/Thr) pro-
tein phosphatase calcineurin, discovered more than 30
years ago [1], is a key factor of a multitude of cell signal-
ling processes, in particular in immune, neuronal and
muscle cells. Targeting the phosphatase activity of cal-
cineurin has revolutionized clinical transplantation. Cal-
cineurin represents a hub of antigen specific T cell
activation and differentiation (Figure 1). Inhibition of cal-
cineurin totally blocks the adaptive immune response.
Therefore, calcineurin is considered as "Achilles' heel of
the immune system" [2].
The Ser/Thr phosphatase calcineurin
Calcineurin, also named protein phosphatase 2B (PP2B),
is a ubiquitously expressed cytosolic Ser/Thr protein phos-
phatase, highly conserved in eukaryotes. Calcineurin con-
sists of two subunits - the enzymatic subunit A and the
regulatory subunit B. The subunit A contains a calmodu-
lin binding site and an autoinhibitory domain, which
blocks the catalytic centre of the enzyme. Binding of Ca2+
ions and calmodulin to calcineurin leads to a change of
conformation and a subsequent unmasking of the active
centre. Thereby, calcineurin activity is coupled to cytosolic
calcium levels, which is a unique property of calcineurin
among the Ser/Thr protein phosphatases [3]. Addition-
ally, activity and localization of calcineurin is modulated
by endogenous proteins, such as RCANs, Cabin1 or
AKAP79. These regulatory proteins have been recently
reviewed in detail [4,5].
Calcineurin and NFATc
Calcineurin has the ability to dephosphorylate a broad
range of proteins [6]. Some of the most important sub-
strates are the transcription factors of the NFATc (nuclear
factor of activated T cells) family: NFATc1 to NFATc4 [7].
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NFATc regulates the expression of many genes by binding
to DNA as dimers or in cooperation with other transcrip-
tion factors. Among the regulated genes are cytokines such
as IL-2, IL-4 and IFNγ or surface proteins such as CD40L
and CD95L [8-10]. NFATc controls the expression of the
endogenous calcineurin inhibitory protein RCAN1-4,
thereby forming a negative feedback loop for the cal-
cineurin-NFATc signalling [11].
Calcineurin seems to be the only protein phosphatase that
dephosphorylates NFATc [12-14]. In resting T cells NFATc
is highly phosphorylated and localized in the cytosol.
Upon stimulation of T cells and subsequent calcium
mobilization activated calcineurin dephosphorylates
NFATc at 13 serine residues in the regulatory region [15],
leading to its nuclear translocation by exposure of the
nuclear localization sequences [16,17]. Concerted rephos-
phorylation of NFATc leads to its translocation into
cytosol and abrogation of NFATc transcriptional activity
[18,19].
NFATc is not only dephosphorylated by calcineurin but
additionally interacts with calcineurin via two motifs
binding at regions distinct from the catalytic centre of cal-
cineurin. These motifs are named calcineurin binding
region (CNBR)1 and CNBR2 or PxIxIT and LxVP accord-
ing to their consensus sequences, respectively [20]. The
PxIxIT region of NFATc binds even to inactive calcineurin
and is responsible for basal NFATc-calcineurin interaction
[21,22]. The LxVP motif interacts just with activated cal-
cineurin, because its binding site at calcineurin is masked
by the autoinhibitory domain [23,24]. Interaction of both
NFATc motifs with calcineurin directs the regulatory
region of NFATc into close vicinity to the active centre of
calcineurin. This enables targeted dephosphorylation of
specific NFATc serine residues by calcineurin. The PxIxIT
calcineurin-binding motif of NFATc is shared by several
other peptides and proteins binding to calcineurin. This
motif may serve as a general calcineurin interface [25,26].
Calcineurin not only modulates the activity of NFATc but
also several other transcription factors such as NF-κB, AP-
1, and Elk1 [27-33]. In addition, calcineurin interferes
with other signalling pathways such as TGF-β-dependent
signalling and the MAPK cascade [33,34]. However, it is
widely unknown, which components of these pathways
are substrates or interaction partners of calcineurin and to
which extent their dephosphorylation modulates the
respective signalling.
In summary, calcineurin is unique in three aspects. First,
it is the only Ca2+-dependent Ser/Thr protein phos-
phatase. Second, to date, only calcineurin is known to
activate the NFATc transcription factors thereby control-
ling the expression of a broad range of genes. Third, the
inhibition of calcineurin activity is so far the only effective
therapeutic strategy to suppress the activation of memory
CD4+ and CD8+ T cells [35,36]. The "classical" drugs tar-
geting calcineurin activity and subsequently inhibiting
NFATc activation are cyclosporin A (CsA) and FK506 (tac-
rolimus). Inhibitors of calcineurin are indispensable for
treatment of transplantation patients and represent a val-
uable tool for basic research.
CsA and FK506 - the classical calcineurin inhibitors
Cyclosporin A (CsA) and FK506 (tacrolimus) are widely
used as effective immunosuppressants in the clinic,
mainly in organ transplantation and dermatology [37-
39]. Application of these compounds in basic research has
Schematic overview about TCR-dependent signalling path- ways Figure 1
Schematic overview about TCR-dependent signalling 
pathways. Engagement of TCRs and costimulatory CD28 
receptors promote signalling cascades of kinases and adaptor 
proteins (yellow). They trigger pathways resulting in the acti-
vation of the transcription factors NFATc (red), NF-κB 
(green) and AP-1 (blue). These transcription factors cooper-
ate with each other during the activation of several genes, 
e.g. IL-2. Of special interest for this review is the calcineurin-
NFATc pathway: IP3, generated by PLCγ (orange) via cleav-
age of PIP2, binds to the IP3 receptor (IP3R) and causes the 
release of Ca2+ from the endoplasmatic reticulum (ER). This 
Ca2+ depletion is sensed by STIM1, which is directly coupled 
to the ORAI CRAC channels. Influx of extracellular Ca2+ into 
the cytosol activates calcineurin (CaN), leading to the 
dephosphorylation and nuclear translocation of NFATc. 
DAG: diacylglycerol; IP3: inositol-1,4,5-trisphosphate; PIP2: 
phosphatidylinositol-4,5-bisphosphate; PKCθ: protein kinase 
C theta; PLCγ: phospholipase C gamma.
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substantially contributed to the elucidation of cal-
cineurin-dependent signalling processes [40,41].
The immunosuppressive properties of CsA were discov-
ered 1976 in animal models [42]. Since 1979 [43,44] CsA
is indispensible for transplantation medicine. In 1987,
FK506 was described as an alternative to CsA [45], fol-
lowed by its first clinical application in 1989 [46]. Despite
the widespread application of both compounds in the
clinics their molecular mechanisms remained unclear
until 1991. Then, Liu et al. identified calcineurin as the
common target of both compounds if and only if they are
complexed with the respective endogenous partners, the
immunophilins. They showed that neither the isolated
immunophilins nor the immunosuppressants alone but
only immobilized immunophilin/immunosuppressant
complexes are able to pull down the calcineurin/calmod-
ulin protein from cellular extracts. These experiments
clearly demonstrated that CsA and FK506 are not active
calcineurin inhibitors by themselves but need binding to
their endogenous matchmaker proteins to be activated in
a gain of function mechanism [47,48]. Immunophilins,
belonging to the class of peptidyl-prolyl cis-trans isomer-
ases (PPIases), are involved in de novo protein folding and
many other cellular functions [49,50]. Binding of CsA or
FK506 to their respective major intracellular acceptor pro-
teins cyclophilin A (CypA) and FK506 binding protein 12
(FKBP12) inhibits their PPIase activity. These CsA- and
FK506-PPIase-complexes are noncompetitive inhibitors
of calcineurin. Thereby, they severely limit the access of
protein substrates to the active centre of calcineurin [51-
54] and mask the docking site for the NFATc LxVP motif
at calcineurin [24]. Thus, they inhibit the dephosphoryla-
tion of physiological targets of calcineurin. However,
small molecular substrates like p-nitrophenyl phosphate
(pNPP) are still being dephosphorylated [55,56]. The
activity of other Ser/Thr protein phosphatases such as
PP1, PP2A or PP2C is not affected by CsA- or FK506-com-
plexes.
Although CsA and FK506 share a similar mode of action,
they belong to different chemical classes. CsA is a fungal
cyclic undecapeptide [57], whereas the bacterial FK506
belongs to the chemical class of macrolides [58,59].
Application of CsA and FK506 inhibits the T cell receptor
(TCR)-dependent activation, proliferation, and differenti-
ation of T cells. Both compounds inhibit the activation of
NFATc and p65/NF-κB [60,61]. However, NF-κB regu-
lated gene transcription is not completely blocked, due to
additional, calcineurin-independent activation pathways
for NF-κB [62]. Other cellular processes, such as CREB
transcripitional activity [63] and proteasomal degradation
of proteins [64,65], are modulated by CsA or FK506 treat-
ment, too.
So far, CsA and FK506 are the only drugs suppressing not
only the activation of naïve and effector TH cells, but in
addition of memory TH cells. Therefore, the application of
these drugs is crucial in particular for transplantation
patients with high numbers of alloreactive memory/effec-
tor T cells, which cannot be controlled with calcineurin-
inhibitor-free treatment protocols [35,66]. However, their
use in clinical routine is often limited by severe side effects
such as nephro- and neurotoxicity [67]. It is not known so
far whether these side effects are mainly due to inhibition
of calcineurin- or immunophilin-dependent mecha-
nisms. Furthermore, it is not clear whether the modula-
tion of the calcineurin-NFATc pathway or of other
pathways and transcription factors cause the adverse side
effects.
To dissect the different actions of CsA or FK506, alterna-
tive inhibitors should ideally discriminate not only
between the inhibition of calcineurin and the other Ser/
Thr protein phosphatases but in addition between the
inhibition of calcineurin and PPIases as well as of NFATc
and other substrates of calcineurin. Compounds having
these properties would be more specific than CsA and
FK506 and might cause fewer side effects in clinical appli-
cations. In basic research such compounds would help to
identify and characterize different targets of calcineurin
[68].
Here we review several novel inhibitors of the calcineurin-
NFATc pathway, which were discovered and partially
characterized in the last decades. We summarize these
inhibitors according to their mode of action (Figure 2),
chemical structure, and inhibitory effects.
Small molecular inhibitors
Binary complex formation with their respective PPIases is
the prerequisite for the ability of CsA and FK506 to inhibit
calcineurin. Thus, application of CsA and FK506 does not
allow the discrimination between effects of these drugs on
calcineurin and on the PPIases, respectively. Therefore,
extensive research was undertaken to synthesize or iden-
tify derivatives of CsA and FK506 with mono-specificity
for either inhibition of calcineurin or of PPIase activity
(Table 1).
CsA derivatives
CsA is a cyclic undecapeptide causing CypA and cal-
cineurin inhibition via different parts of the molecule.
CsA residues 2-9 are responsible for CypA binding, while
CsA residues 4-7 are involved in calcineurin binding.
Modifications in position 3 [69], position 6 [70,71] or
position 8 [72] resulted in some CsA derivatives, such as
[(S)α-methylthiosarcosine3]-CsA,  [N-Methyl-Ala6]-CsA
and  [D-Diaminopropyl8]-CsA, which bind to CypA butCell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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are not able to inhibit calcineurin's activity, neither in
their uncomplexed form nor in the complex with CypA.
Several other CsA derivatives substituted in position 3, e.g.
[(R)α-Methylsarcosine3]CsA  and
[Dimethylaminoethylthiosarcosine3]CsA  have been
found to inhibit calcineurin without prior formation of a
complex with cyclophilin 18 or inhibition of its isomerase
activity. However, both compounds show affinity towards
CypA and can therefore not be considered monospecific
[73].
Modifications of CsA in the position 1 change the affinity
of the derivatives towards CypA. The derivative
[MeBm2t]1-CsA  has a lower binding affinity than CsA
[74], but the binary complex retains the immunosuppres-
sive capacity. The derivative ISA247 (voclosporin) has a
higher affinity to CypA than CsA [75,76] and has the
potential to be administered in lower concentrations.
Therefore it might be less toxic than CsA and is under
investigation in phase II and III trials for psoriasis patients
[77,78].
FK506 derivatives
FK506 has several derivatives with the same mode of
action. Among them are the immunosuppressive com-
pounds  FK520  (ascomycin) and pimecrolimus. Other
FK506 derivatives are monospecific for FKBP12 binding
and inhibition, such as L-685,818 (FK506BD) [79] and V-
Inhibition of the calcineurin-NFATc pathway at multiple levels Figure 2
Inhibition of the calcineurin-NFATc pathway at multiple levels. Upon receptor induced Ca2+ entry into the cell, cal-
modulin (CaM) and calcineurin B (CaNB) bind Ca2+ ions and activate calcineurin by inducing a conformational switch of the 
subunit A (CaNA). Activated calcineurin binds NFATc via the PxIxIT and the LxVP motifs of NFATc and subsequently dephos-
phorylates the transcription factor. Dephosphorylated NFATc exposes its nuclear localization sequence (NLS) and is therefore 
shuttled into the nucleus, where it binds to the appropriate DNA sequences. NFATc exerts its transactivation effects often in 
combination with another transcription factor (TF). NFATc is deactivated by rephosphorylation and subsequent translocation 
into the cytosol. Different steps in this pathway are targeted by certain compounds to finally suppress NFATc-dependent gene 
expression. A selection of the most important and best characterized inhibitors of calcineurin-NFATc signalling is shown (in 
red) at their point of interference. AID: autoinhibitory domain of calcineurin A; TCR: T cell receptor.
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Table 1: Low molecular weight inhibitors of calcineurin-NFATc signalling
Inhibitor Mode of action IC50/Kd*/Ki** References
General protein phosphatase inhibitors inhibiting also calcineurin (CaN)
Endothall binds to the active centre of PP1, PP2A, CaN 11,5 μM** a Tatlock JH 1997 [195]
FMPP binds covalently to the active centre of PP1, PP2A, CaN 44 mMb Born TL 1995 [88]
Norcantharidin binds to the active centre of PP1, PP2A, CaN 31 μMb Steward SG 2007 [90]
Okadaic acid binds to the active centre of PP1, PP2A, CaN 4.6 μMb Bialojan C 1988 [196]
Tyrphostins bind possibly to the active centre of PP1, PP2A, CaN 21 - 62 μMb Martin BL 1998 [89]
Inhibitors of calcineurin-dependent signalling - CsA, FK506 and derivatives
CsA/CypA complex blocks substrate access to the active centre of CaN 7 nMa Fruman DA 1992 [197]
ISA247/CypA complex blocks substrate access to the active centre of CaN ~100 nMa Aspeslet L 2001 [75]
[Dat-Sar]3-CsA blocks substrate access to CaN independent of CypA 1 μMa Baumgrass R 2004 [73]
FK506/FKBP12 complex blocks substrate access to the active centre of CaN 0.4 nMa Fruman DA 1992 [197]
Ascomycin/FKBP12 complex blocks substrate access to the active centre of CaN 0.7 nMm Sinclair PJ 1996 [198]
Pimecrolimus/FKBP12 complex blocks substrate access to the active centre of CaN 0.4 nMa Grassberger M 1999 [82]
Inhibitors of calcineurin-dependent signalling - alternative inhibitory compounds
1,5-dibenzoyloxymethyl-norcantharidin binds to the active centre of CaN 7 μMa Baba Y 2003 [101]
AM404 inhibits NFATc-DNA binding 10 μMc Caballero FJ 2007 [132]
BTP1 inhibits of NFATc dephosphorylation in cells 60 nMd Trevillyan JM 2001 [118]
BTP2 decreases Ca2+ influx into cytosol 10 nMc Ishikawa J 2003 [119]
Dibefurin inhibits enzymatic activity of CaN 44 μMe Brill GM 1996 [110]
Dipyridamole disrupts CaN-NFATc binding ~10 μMa Mulero C 2009 [111]
Gossypol inhibits enzymatic activity of CaN 17 μMa Baumgrass R 2001 [199]
INCA1 0.5 μM* f Roehrl MH 2004 [114]
INCA2 disturb CaN-NFATc complex formation by covalent binding 
to CaN
0.12 μM* f Roehrl MH 2004 [114]
INCA6 0.8 μM* f Roehrl MH 2004 [114]
Kaempferol inhibits enzymatic activity of CaN 51.3 μMa Wang H 2008 [94]
Lie120 inhibits enzymatic activity of CaN 5 μMa Klettner A 2001 [80]
NCI3 disturbs CaN-NFATc binding in cells 2 μMc Sieber M 2007 [113]Cell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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10,367 [80]. However, so far there are no FK506 deriva-
tives with monospecific action on calcineurin.
Several of the immunosuppressive derivatives have been
characterized in detail.
FK520 [81] is a naturally occurring FK506 derivative con-
taining an ethyl group in the position 21 and is used as an
immunosuppressant in vitro and in rodent models. Sev-
eral semisynthetic immunosuppressive compounds are
derived from FK520. Pimecrolimus (SDZ AM 981, 33-
epi-chloro-33-desoxy-ascomycin) [82], is routinely used
in the topical treatment of inflammatory skin diseases. It
is more lipophilic than FK506 and therefore more affine
to the skin, has low systemic effects, and does not induce
skin atrophy, in contrast to topical steroids. The derivative
L-732,531  (32-O-(1-hydroxyethylindol-5-yl)-ascomy-
cin) binds poorly to FKBP12, but the stability of the L-
732,531-FKBP12-calcineurin-complex is much higher
compared to the complex with FK506 [83]. This might be
the reason that L-732,531 has less severe side effects in a
murine transplant model [84].
Interestingly, FK506 and its related, naturally occurring
immunosuppressive compound rapamycin  (sirolimus)
share the FKBP-binding domain but differ in their effector
PD 144795 inhibits enzymatic activity of CaN ~3 μMa Gualberto A 1998 [109]
Roc-1 enhances rephosphorylation and nuclear export of NFATc 5~25 nMc Proksch P 2005 [136]
ST1959/DL111-IT enhances nuclear export of NFATc 13.5 μM Lindstedt R 2009 [128]
Thiopental inhibits CaM-dependent activity of CaN 0.18 mMa Humar M 2004 [97]
Trifluoperazine inhibits binding of CaM to CaN 8 μMg Aussel C 1995 [144]
Tropisetron inhibits CaN-dependent NFATc transactivation ~50 μMc Vega Lde L 2005 [138]
UR-1505 inhibits NFATc binding to DNA 100~300 μMh Román J 2007 [133]
WIN 53071 alters NFATc binding to DNA 3.4 μMh Baine Y 1995 [141]
Inhibitors of calcineurin-dependent signalling - unknown mode of action
Caffeic Acid Phenethyl Ester N.D. 0,1~1 μMc Marquez N 2003 [146]
KRM-III N.D. 5 μMc Jung EJ 2009 [145]
NFAT-68 N.D. 0.63 μMc Burres NS 1995 [152]
YM-53792 N.D. 50 nMc Kuromitsu S 1997 [149]
Punicalagin N.D. < 5 μMg Lee SI 2008 [153]
Imperatorin N.D. 37 μMc Marquez N 2004 [154]
Quinolone alkaloid compounds 1 and 3 N.D. 3.4 μMc Jin HZ 2004 [155]
Impressic acid N.D. 12.6 μMc Cai XF 2004 [159]
oleanane triterpenoid compound 3 N.D. 4.6 μMc Dat NT 2004 [162]
Gomisin N N.D. 1.33 μMc Lee IS 2003 [163]
N.D.: not determined
Indicated methods for IC50/Kd/Ki determination: a - phosphatase assay on RII phosphopeptide; b - phosphatase assay on pNPP; c - NFAT dependent 
reporter gene expression; d - IL-2 promoter dependent reporter gene expression; e - phosphatase assay on 4-methylumbelliferyl phosphate; f - 
displacement of VIVIT peptide; g - IL-2 secretion assay; h -EMSA for NFATc; i - interference with CaN-NFATc binding assay; k - binding assay to 
CaN; l - phosphatase assay on NFATc; m - cell proliferation assay
Table 1: Low molecular weight inhibitors of calcineurin-NFATc signalling (Continued)Cell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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domains [85]. Rapamycin/FKBP12 does not bind to cal-
cineurin [47], but exerts its immunosuppressive and anti-
proliferative effects via inhibition of the mTOR/Akt
signalling. This signalling node is part of costimulatory
and IL-2 receptor signalling pathways [86]. Rapamycin is
often used in clinical routine in prolonged treatment of
transplantation patients after initial CsA or FK506 appli-
cation. Rapamycin suppresses posttransplantational
malignant neoplasia due to its antiproliferative properties
[87].
Inhibitors acting on the calcineurin molecule
The catalytic centre of calcineurin (PP2B) shares the struc-
ture and conformation with other Ser/Thr protein phos-
phatases, namely PP1 and PP2A. Therefore, several
inhibitors targeting the active centre of calcineurin addi-
tionally inhibit these protein phosphatases, too. Among
them are 4-(fluoromethyl)phenyl phosphate (FMPP)
[88], tyrphostins  [89] and norcantharidin  [90]. How-
ever, some inhibitors, such as okadaic acid or endothall,
show different affinities towards different phosphatases.
By using selected concentration ranges of these inhibitors
it is possible to inhibit mainly PP1 and PP2A, but cal-
cineurin to a lower degree. Okadaic acid inhibits PP1 and
PP2A in nanomolar, but calcineurin in micromolar con-
centrations [91]. Pyrethroid insecticides do not possess
any ability to inhibit calcineurin [92,93], contrary to an
earlier report.
The following compounds (Table 1; see additional file 1
for IUPAC names or chemical structures) inhibit cal-
cineurin specifically among the Ser/Thr protein phos-
phatases. They might act mainly as noncompetitive
inhibitors, such as CsA and FK506, but in contrast to them
they do not need a matchmaker protein.
Kaempferol, a natural flavonol, inhibits the phosphatase
activity of purified calcineurin against pNPP and RII phos-
phopeptide. Kaempferol binds to the catalytic domain of
calcineurin A and acts independently of any matchmaker
protein. Protein phosphatase 1 and alkaline phosphatase
activity are not inhibited by this compound. Kaempferol
suppresses IL-2 gene expression in Jurkat T cells [94,95].
Surprisingly, it also inhibits the calcineurin-independent
TNFα-induced NF-κB activation in HEK293 cells [96].
Barbiturates such as thiopental, pentobarbital, thiamylal
and secobarbital are inhibitors of the phosphatase activity
of calcineurin [97]. They inhibit the calmodulin-mediated
dephosphorylation of the RII  phosphopeptide [55] in
enzymatic assays, as well as NFATc dephosphorylation,
NFATc nuclear translocation and cytokine production in T
cells. These effects do not depend on binding of the bar-
biturates to their GABA receptor and its subsequent signal-
ling. Additionally, barbiturates inhibit AP-1 activation
independently of calcineurin [98]. Thiopental suppresses
NF-κB activation via unknown mechanisms [99]. In lym-
phocytes, thiopental decreases antigen- but not mitogen-
induced proliferation, IL-2 expression and IFNγ expres-
sion [100].
1,5-dibenzoyloxymethyl-norcantharidin  is a derivative
of norcantharidine [101,102]. Among other compounds,
it was synthesized according to a computational interac-
tion model of norcantharidin carboxylate with the cata-
lytic centre of calcineurin. It has been selected by
screening for specific binding to calcineurin, but not to
PP1 and PP2A. 1,5-dibenzoyloxymethyl-norcantharidin
inhibits the dephosphorylation of pNPP and the RII phos-
phopeptide by calcineurin. However, no data about inhi-
bition of protein dephosphorylation in cell-free assays or
in cells have been reported for this compound.
Gossypol, a cell permeable polyphenole identified in cot-
ton plants, inhibits noncompetitively the enzymatic activ-
ity of calcineurin but of none of the other Ser/Thr protein
phosphatases. The inhibition of pNPP and RII  phos-
phopeptide dephosphorylation is reversible and is inde-
pendent of immunophilins or other matchmaker
proteins. Gossypol inhibits the nuclear translocation of
NFATc in activated T cells. The reported effect of gossypol
on calcineurin-calmodulin interaction [103] cannot
account for these specific effects, as gossypol only partially
prevents the binding of calmodulin to calcineurin and just
at very low concentrations of calmodulin. Gossypol
shows immunosuppressive effects in mice [104] and
inhibitory effects on growth, cell signalling and develop-
ment in Dictyostelium cells. These effects are specific for
calcineurin as they can be diminished by calcineurin over-
expression [105]. However, gossypol has been reported to
additionally inactivate other enzymes than calcineurin
such as dehydrogenases [106], phospholipase A2 [107]
and topoisomerase II [108].
Lie120, a thiazole derivative, inhibits the enzymatic activ-
ity of calcineurin but not the PPIase activity of FKBPs or
cyclophilins. Dephosphorylation of pNPP and RII phos-
phopeptide is inhibited by Lie120 in cell-free assays. In
neuronal cell lines it prevents the FK506-sensitive H2O2-
triggered activation of JNK. However, Lie 120 is toxic at
concentrations higher than 5 μM [80].
PD 144795, a benzothiophene derivative, blocks the
enzymatic activity of calcineurin in cell lysates. In Jurkat T
cells transfected with an HIV-1 LTR fragment, PD 144795
inhibits the calcineurin-dependent binding of p53 and
NF-κB to the HIV promoter element. These inhibitory
effects are abolished by overexpression of calcineurin
[109].Cell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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Dibefurin, a fungal phenolic compound, inhibits the
enzymatic activity of calcineurin against the small molec-
ular substrate 4-methylumbelliferyl phosphate. Further-
more, it shows suppressive effects in both assays, mixed
lymphocyte reaction (MLR) and lymphocyte cytotoxicity
analysis [110].
Compounds inhibiting the enzymatic activity of cal-
cineurin are supposed to block the dephosphorylation of
all protein substrates. Therefore, only compounds target-
ing specific calcineurin-substrate interactions but not the
general phosphatase activity of calcineurin might be able
to dissect the action of calcineurin on different substrates.
Recently, different efforts were made to identify such com-
pounds, interfering specifically with calcineurin-NFATc
interactions in T cells.
Dipyridamole, a drug clinically used for stroke treatment,
is suggested to affect the interaction of NFATc with cal-
cineurin, because it competes with fluorescence-labelled
RCAN1-CIC peptide (see below) for binding to cal-
cineurin. Dipyridamole does not interfere with the phos-
phatase activity of calcineurin on RII phosphopeptide in
cell-free assays. It suppresses ionomycin-induced NFATc2
nuclear translocation in Jurkat T and U-2 osteosarcoma
cell lines, and blocks subsequently NFATc-dependent
reporter gene and cytokine expression [111]. Dipyrida-
mole inhibits TNFα production in activated PBMC [112].
NCI3, a pyrazolopyrimidine derivative, does not influ-
ence the enzymatic activity of calcineurin in cell-free sys-
tems. However, NCI3 inhibits NFATc dephosphorylation
and nuclear translocation, IL-2 secretion and cell prolifer-
ation upon stimulation of Jurkat or primary human T
cells. NFATc-dependent reporter gene expression is more
sensitive to NCI3 than NF-κB, whereas AP-1-dependent
transcription is not influenced. These effects are dimin-
ished by calcineurin overexpression. An effect of NCI3 on
the calcineurin-substrate interface is postulated as it par-
tially displaces the VIVIT peptide, an oligopeptide derived
from the PxIxIT-calcineurin binding motif of NFATc (see
below) [113].
INCA compounds are a group of chemically unrelated
substances selected in a screening for inhibition of NFATc-
calcineurin interaction. INCA-1, 2 and 6 bind covalently
but reversibly to calcineurin at the residue Cys266. Subse-
quently, steric changes mask the binding site for NFATc
and VIVIT peptide. INCA-2, but not INCA-6, inhibits the
enzymatic activity of calcineurin. INCA-6 inhibits the
dephosphorylation of NFATc and its nuclear import in
ionomycin-stimulated Cl.7W2 murine T cell line and,
consequently, the expression of IFNγ and TNFα. However,
general cytotoxicity has been reported for all INCA com-
pounds, ruling out their use in primary cells [114,115].
Inhibitors not acting directly on the calcineurin molecule
Inhibitors of calcineurin-NFATc signalling may not only
act on calcineurin itself, but also up- or downstream of the
calcineurin-NFATc interaction or dephosphorylation
processes. Among the possibilities are effects of com-
pounds on calcium mobilization, on the nuclear translo-
cation of NFATc or on NFATc-DNA-binding (Figure 2).
Inhibitors acting downstream of calcineurin activation
might be more specific to suppress just NFATc activation
than CsA or FK506 complexes.
BTPs or 3,5-Bis(trifluoromethyl)pyrazoles are a batch of
NFATc modulators with different modes of action
[116,117].
BTP1 and BTP3 (compounds 1 and 2 in Djuric et al.) are
supposed to interfere with calcineurin-dependent NFATc
activation, because calcineurin activity against RII phos-
phopeptide and phosphorylated Elk1 is not inhibited in
enzyme assays and in cell lysates. BTP1 and BTP3 dimin-
ish activation-dependent NFATc dephosphorylation, its
nuclear translocation in primary T cells and cell lines as
well as subsequent cytokine production and cell prolifer-
ation. It is assumed that NF-κB or AP-1 activation are not
affected by BTP1 and BTP3 [118].
BTP2 (compound 3 in Djuric et al., alternative name YM-
58483) dose-dependently enhances TRPM4, a Ca2+-acti-
vated nonselective cation channel. Thereby, BTP2
decreases CRAC-channel-dependent Ca2+ influx due to
depolarization of lymphocyte cell membranes. Subse-
quently, the activation of calcineurin is diminished, lead-
ing to a reduced NFATc-driven promoter activity and IL-2
production in Jurkat T cells. AP-1-driven promoter activity
is not influenced. BTP2 also inhibits the proliferation and
Ca2+-dependent cytokine production in stimulated
human CD4+ T cells [119-121] and the expression of IL-4
and IL-5 in an antigen-stimulated murine TH2 T cell clone.
In vivo studies show an inhibition of antigen-induced air-
way-inflammation [122], of donor anti-host cytotoxic T
lymphocyte activity and IFNγ production in graft versus
host disease, and of delayed-type hypersensitivity
response in mice [123]. Inhibition of Ca2+-dependent
functional responses of human neutrophils and granulo-
cyte-differentiated HL60 cell line was also observed [124].
However, it is unclear to which extent these observed
effects are caused by inhibition of calcineurin, because
other Ca2+-dependent processes are suppressed, too. In
particular, the activation of the calmodulin-dependent
kinases (CaMK) plays an important role in T cell activa-
tion and inflammatory responses.
BTP A-285222 (compound 19 in Djuric et al.) has immu-
nosuppressive effects in an animal model but exhibits
severe side effects, such as neurotoxicity. The molecularCell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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mode of action of BTP A-285222 is not known, neverthe-
less many effects on different cell types are observed. It
was found that cytokine production of T cells is reduced
by 80% in BTP A-285222-treated mice [125], that agonist-
induced NFATc3-dependent IL-6 production is inhibited
in myometrial arteries and that proliferation of isolated
vascular smooth muscle cells is impaired [126,127].
ST1959, a 3,5-diaryl-s-triazole derivative which is also
named DL111-IT/contragestazol, inhibits T cell activa-
tion, proliferation and cytokine production by enhancing
the nuclear export of NFATc2. NFATc2 de- and rephos-
phorylation are not influenced. NF-κB- and AP-1-depend-
ent gene transcription are reported to be not affected
[128]. The compound shows immunosuppressive effects
in several animal models of autoimmune diseases, such as
colitis and host versus graft disease [129,130].
AM404, a product of the acetaminophen (paracetamol)
catabolism [131], inhibits NFATc2-DNA binding and
transcriptional activity in Jurkat T cells, but not in cell
lysates. It is postulated that AM404 inhibits the nuclear
translocation of dephosphorylated NFATc. AM404 does
not inhibit Ca2+ influx, disturbs only slightly the dephos-
phorylation of NFATc2 in cells and does presumably not
interfere with the signalling pathways leading to NF-κB or
AP-1 activation. However, AM404 suppresses IL-2 and
TNFα transcription, T cell proliferation and cytokine
release in Jurkat T cells after αCD3/28 stimulation [132].
UR-1505 is a pentafluoropropoxy derivative of salicylic
acid [133]. It blocks the binding of NFATc to DNA upon
ionomycin stimulation but has no effect on the nuclear
translocation of NFATc. Therefore, UR-1505 effects are
not due to NFATc-export inhibition or enhanced re-phos-
phorylation. The activation of NF-κB and AP-1 seems to
be not affected. UR-1505 inhibits αCD3/CD28-induced,
but not JAK/STAT-induced T cell proliferation and IL-5 as
well as IFNγ expression. UR-1505 shows anti-inflamma-
tory properties in rat colitis models [134]. Triflusal,
another salicylic acid derivative, inhibits not only NFATc-
DNA complex formation, but additionally NF-κB activa-
tion [135].
Rocaglamide derivatives Roc-1, 2 and 3 inhibit the acti-
vation-induced NFATc1 translocation into the nucleus. It
is supposed that elevated kinase activities of p38 MAPK
and JNK by Roc-1, 2 and 3 cause an increased NFATc re-
phosphorylation. This inactivation of NFATc leads to a
reduced expression of IL-2, IL-4, IFNγ and TNFα. The
nuclear localization of c-Jun, a potential subunit of AP-1,
is also inhibited. Surprisingly, only NFATc- but not AP1-
or NF-κB-dependent reporter gene transcription is sup-
pressed by the inhibitors in the selected concentration
range (up to 100 nM) [136].
Tropisetron, an antagonist of the serotonin receptor,
inhibits NFATc-dependent signalling caused by overex-
pression of the constitutively active calcineurin construct
ΔCaM-AI [137]. Therefore, a target at or downstream of
calcineurin activity was suggested. Tropisetron inhibits
the transcriptional activities of NFATc, NF-κB and AP-1 in
PMA/ionomycin-, but not TNFα-stimulated Jurkat T cells.
Tropisetron suppresses the phosphorylation of p38 MAPK
and JNK but not the phosphorylation of ERK 1 and 2. It
inhibits IL-2 production in primary T cells upon SEB stim-
ulation [138]. Tropisetron ameliorates acetic-acid-
induced colitis in rats [139].
Venkatesh et al. selected 14 compounds in a screening of a
library with 16,000 substances for inhibitors of GFP-
NFATc3 nuclear translocation in HeLa cells. Most of them
interfered with calcium mobilization and therefore cal-
cineurin activation [140].
WIN 53071 alters NFATc-DNA complex formation in
intact cells but not in cell-free binding assays. It does not
inhibit the enzymatic activity of calcineurin against RII
phosphopeptide. WIN 53071 inhibits Ca2+-dependent IL-
2 expression in primary human lymphocytes, MLR and
NFATc-driven reporter gene expression [141].
Trifluoperazine  binds to calmodulin and inhibits its
interaction with calcineurin [142]. Therefore, trifluopera-
zine inhibits calcineurin activation and suppresses the
dephosphorylation of RII phosphopeptide in cell lysates
[143] and IL-2 expression of αCD3/PMA-activated Jurkat
T cells. Due to its mode of action, also other calmodulin-
dependent but calcineurin-independent processes are
modulated, such as phosphatidylserine synthesis [144].
Inhibitors with unknown mode of action
Several compounds, belonging to different chemical
classes, were found to inhibit NFATc-dependent gene
expression and other NFATc-mediated cellular effects.
However, the underlying molecular mechanisms of the
compounds listed in this chapter were not elucidated in
detail by the respective authors.
KRM-III  inhibits NFATc-, but not NF-κB-dependent
reporter gene expression in PMA/ionomycin stimulated
Jurkat T cells. KRM-III diminishes the proliferation of
TCR-stimulated murine T cells and MLR. Upon oral appli-
cation to mice, KRM-III reduces the IL-2 levels in blood
after αCD3-injection, and diminishes delayed type hyper-
sensitivity responses and MOG-induced experimental
autoimmune encephalomyelitis [145].
Caffeic Acid Phenethyl Ester (CAPE), a phenolic com-
pound derived from honey bee propolis, inhibits IL-2
promoter activity and cytokine synthesis, NF-κB bindingCell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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to DNA in PMA-stimulated Jurkat cells (but not IκBα deg-
radation), NFATc dephosphorylation after PMA/ionomy-
cin stimulation, and the DNA binding of a pGal4-
NFATc2(1-415) fusion protein in cells. CAPE inhibits not
only the percentage of cells expressing the activation
markers CD25, CD69, and ICAM-1 at the cell surface but
also the relative intensity of fluorescence in the positive
cell population [146]. It is a potent inhibitor of antigen-
and mitogen-induced T-cell proliferation, cytokine pro-
duction [147], and NF-κB activation [148]. The precise
mode of action of CAPE remains unclear.
YM-53792 suppresses NFATc-, but not AP-1- and NF-κB-
driven promoter activities and the formation of NFATc-
DNA complexes in stimulated Jurkat cells. YM-53792
inhibits IL-2 gene promoter activity and the expression of
IL-2, IL-4 and IL-5 in stimulated human peripheral blood
mononuclear cells. It was assumed that YM-53792 specif-
ically inhibits the calcineurin-NFATc pathway, but the
molecular mechanism is not elucidated [149].
Quinazolinediones  and  pyrrolopyrimidinediones,
selected by screening of a compound library, inhibit
NFATc-dependent reporter gene transcription in Jurkat
cells [150]. No further examination of their mode of
action has been reported. Recent data suggest that the
inhibitory effect of quinazolinediones such as WIN 61058
[141] is independent of calcineurin but due to inhibition
of the monocarboxylate transporter MCT1, which is cru-
cial in the export of catabolic lactate from activated blastic
T cells [151].
NFAT-68 and NFAT-133 are no proteins but in fact fungal
aromatic compounds. They do not interfere with cal-
cineurin phosphatase activity against 4-methylumbellif-
eryl phosphate, but inhibit NFATc-driven reporter gene
transcription, MLR and lymphocyte toxicity [152].
Many traditional medical plants, parts of plants or specific
preparations from them often have anti-inflammatory
properties. To identify the responsible natural ingredients
and to search for novel calcineurin-NFATc-pathway inhib-
itors, different libraries were recently screened for inhibi-
tors of NFATc-dependent reporter gene expression.
Unfortunately, most of the selected compounds were not
further characterized concerning their mode of action and
their effects on the inhibition of other transcription fac-
tors and pathways.
Punicalagin, isolated from the fruit of Punica granatum,
inhibits NFATc nuclear translocation and DNA binding. It
diminishes αCD3/28-induced IL-2 production of CD4+ T
cells and shows slight suppression of MLR. Immunosup-
pressive effects of punicalagin were observed in a PMA-
induced edema mouse model [153].
Imperatorin  isolated from Oppopanax chironium(L.), a
furanocumarin, inhibits both NFATc transcriptional and
DNA-binding activities. It blocks the expression of the
reporter gene luciferase controlled by NFATc- or IL-2-
dependent promoter region, but not the expression under
control of an NF-κB- or AP-1-dependent promoter. Imper-
atorin suppresses the proliferation of SEB-stimulated T
cells [154].
Quinolone alkaloids from the Evodia rutaecarpa fruit
inhibit NFATc- and NF-κB-dependent reporter gene
expression in Jurkat T cells. Several of these alkaloids sup-
press NFATc signalling stronger than NF-κB without
affecting the viability of the Jurkat T cell line [155].
Several compounds, extracted from of Asian plants,
inhibit NFATc-dependent reporter gene expression: phe-
nolic constituents 2 and 3 of  Desmos chinensis [156],
gymnasterkoreayne G, a polyacetylene isolated from the
leaves of Gymnaster koraiensis [157], compound 1 from
Ribes fasciculatum var.  chinense  [158],  Impressic acid
[159], lignans [160], and diterpenoids [161], contained
in  Acanthopanax koreanum root,  oleanane triterpenoid
compound 3, contained in the fruits of Liquidambar for-
mosana, [162], as well as gomisin N and schisandrol A,
lignans from Schisandra chinensis [163].
Inhibitory peptides and proteins from pathogens
Protein domains from interaction partners of calcineurin
are usually the point of origin to design inhibitory pep-
tides. These specific peptides, targeting the binding of cal-
cineurin to selected partners and substrates, might be
more specific than CsA- or FK506-complexes (Table 2).
They should help to delineate the interaction mechanisms
of calcineurin interaction with other signalling partners.
Additionally, modifications of these peptides such as frag-
ment shortening and point mutations will support these
efforts. However, often these peptides have low cell mem-
brane permeability, even when they are synthesized with
specific modifications such as leading peptide sequences
containing oligo-arginines.
Inhibitory peptides
AID fragments, derived from the autoinhibitory domain
of the calcineurin A subunit were the first examined inhib-
itory peptides for calcineurin. These peptides, containing
the residues 424-521 (AID424-521), are potent inhibitors of
the phosphatase activity by blocking the access of protein
substrates to the catalytic centre of calcineurin [164]. A
peptide spanning the residues 457-482 (AID457-482) of cal-
cineurin represents the core inhibitory motif [165,166].
This peptide is already able to suppress the dephosphor-
ylation of the RII phosphopeptide in phosphatase assays.
However, additional autoinhibitory elements are present
within the calcineurin region 420-457. Therefore, the pep-Cell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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tides containing the extended AID region AID420-511 and
AID328-511 were three- to fourfold more potent to inhibit
RII phosphopeptide dephosphorylation compared to the
AID457-482 peptide [167]. The 11R-AID457-482 peptide, con-
taining eleven arginine residues, is reported to be indeed
cell-permeable for selected cell types. It inhibits apoptosis
of excitatory neurons [168] and caerulein-induced
zymogen activation in pancreatic acinar cells [169].
PxIxIT peptides are derived from the conserved cal-
cineurin-docking motif PxIxIT found in NFATc and other
proteins [170]. Peptides or protein fragments containing
the PxIxIT element compete with NFATc for binding to
calcineurin and impair thereby the binding and dephos-
phorylation of NFATc1, c2 and c4 in cell-free enzyme
assays. In cells overexpressing PxIxIT peptides, the phos-
phatase activity of calcineurin and therefore the dephos-
phorylation of other substrates are not impaired [21-
23,25].
The  VIVIT 16 mer oligopeptide, designed by selective
amino acid exchange, possesses 25 times higher efficiency
to inhibit NFATc dephosphorylation compared to the
original NFATc2 16 mer SPRIEIT peptide [171]. Overex-
pression of GFP-VIVIT fusion protein in Jurkat T cells
inhibits NFATc- but not NF-κB-dependent reporter gene
expression. Therefore, the VIVIT peptide is more selective
than CsA and FK506 complexes which inhibit the activa-
tion of both transcription factors. 11R-VIVIT peptide is
claimed to be cell-permeable in selected cell types [172],
but there are contrary experimental experiences.
A peptide derived from the calcineurin-anchoring protein
AKAP79 containing the PIAIIIT motif (AKAP79330-357)
binds to purified calcineurin. In contrast to other PxIxIT
peptides, this motif inhibits the phosphatase activity
against the RII  phosphopeptide. Overexpression of
AKAP79330-357 in HEK293 cells antagonizes the interac-
tion between AKAP79 and calcineurin [173].
Table 2: Peptides and proteins inhibiting calcineurin-NFATc signalling
Inhibitor peptide Mode of action IC50/Kd*/Ki** References
CaN457-482-AID 10 μMa Perrino BA 1999 [167]
mask the active centre of CaN
CaN424-521-AID 2.5 μMa Sagoo JK 1996 [164]
mNFATc2106-121 - SPRIEIT 12 μMi Aramburu J 1998 [21]
block CaN-NFATc interaction
VIVIT peptide 0.5 μM* k
< 1 μMl
Roehrl MH 2004 [114]
Aramburu J 1999 [171]
AKAP79330-357 blocks CaN-NFATc interaction 1.5 μMa Dell'Acqua ML 2002 [173]
RCAN1 60 nM* k Chan B 2005 [177]
RCAN1-4141-197 - exon7 block CaN-NFATc interaction 70 nM* k Chan B 2005 [177]
RCAN1-4143-163 - CIC peptide 1.25 μM* k Mulero MC 2009 [111]
LxVPc1 peptide blocks CaN-NFATc interaction and modulates enzymatic 
activity of CaN
~3 μMa Rodriguez A 2009 [24]
RCAN1-495-118 - SP repeat peptide masks the active centre of CaN 91.5 μM** a Vega RB 2002 [185]
VacA inhibits translocation of NFATc N.D. Gebert B 2003 [187]
A238L N.D. Miskin JE 1998 [190]
block CaN-NFATc interaction
A238L200-213 0.6 μMk Miskin JE 2000 [194]
N.D.: not determined
Indicated methods for IC50/Kd/Ki determination: a - phosphatase assay on RII phosphopeptide; b - phosphatase assay on pNPP; c - NFAT dependent 
reporter gene expression; d - IL-2 promoter dependent reporter gene expression; e - phosphatase assay on 4-methylumbelliferyl phosphate; f - 
displacement of VIVIT peptide; g - IL-2 secretion assay; h - EMSA for NFATc; i - interference with CaN-NFATc binding assay; k - binding assay to 
CaN; l - phosphatase assay on NFATc; m - cell proliferation assayCell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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The endogenous inhibitory protein CABIN1 contains a
conserved PEITVT motif. A peptide spanning the residues
2078-2115 of rat CABIN1 binds to calcineurin [174], and
human CABIN12143-2220 overexpression in Jurkat T cells
inhibits NFATc dephosphorylation and NFAT-dependent
luciferase expression [175]. Both fragments overlap at the
KFPPEITVTPP sequence. Therefore, this motif is assumed
to participate in the CABIN1-calcineurin interaction.
RCAN1, an endogenous modulator of calcineurin activity
(also named DSCR1 or calcipressin1), is expressed in sev-
eral splice variants which differ in their N termini but
share an identical C terminus. In this review, the amino
acid designation has been adapted from the splice variant
RCAN1-4 [176], although several cited publications use
the designation of the splice variant 1-1. RCAN1-exon7
(RCAN1-4 residues 141-197), containing the C-terminus,
binds to full-length calcineurin and to a catalytic core frag-
ment of calcineurin as well as full-length RCAN1. Both,
RCAN1-exon7 and full-length RCAN1, inhibit competi-
tively the dephosphorylation of pNPP in enzyme assays
and the calcineurin-mediated nuclear translocation of
NFATc3 in the BHK cell line after their overexpression
[177]. Initially, the PKIIQT motif in this region (RCAN1-
4181-186) was considered to mimic the NFATc PxIxIT motif
and to inhibit NFATc-calcineurin interaction, but a pep-
tide spanning the residues 178-191 did not compete with
VIVIT peptide for binding to calcineurin. Recent experi-
ments revealed that the RCAN1-4136-163 fragment contains
a region named calcineurin-inhibitor calcipressin 1 (CIC)
motif, which is displaced from calcineurin by the VIVIT
peptide [178]. The RCAN1-4143-163 CIC fragment binds to
calcineurin A with high affinity, competes with the bind-
ing of VIVIT peptide, and inhibits NFATc2 nuclear trans-
location as well as NFATc-dependent reporter gene
expression in transfected COS-7 cells. Importantly, this
fragment does not interfere with the phosphatase activity
of calcineurin towards RII phosphopeptide and homolo-
gous regions are found in the related proteins RCAN2
(residues 147-167) and RCAN3 (residues 183-203) [111].
This fragment contains the "true" PxIxIT motif of RCANs
- PSVVVH, which binds to the same hydrophobic pocket
of calcineurin as the VIVIT peptide. Therefore, the PSV-
VVH peptide (RCAN1-4149-166) competes with the regula-
tory region of NFATc2 or GST-CABIN1 for binding to
calcineurin [179].
A peptide derived from the C-terminus of the yeast RCAN
homologue Rcn2 (Rcn2252-265), containing the PSITVN
motif, is able to compete with the VIVIT peptide for bind-
ing to human calcineurin, too. Consequently, deletion of
this motif in Rcn2 abolishes its inhibition of calcineurin
signalling in yeast [180].
The African Swine Fever Virus protein A238L contains a
similar motif the PKIIITG motif (see below).
LxVP peptides are derived from the conserved cal-
cineurin-docking NFATc motif LxVP and compete with
NFATc for the binding to activated calcineurin. The NFATc
isoforms differ in the affinity of their LxVP motifs towards
calcineurin [181].
Pep3  is derived from the CNBR2 of NFATc3 (residues
321-406 of murine NFATc3). This 16-amino acid oli-
gopeptide (mNFATc3385-400) contains the LxVP motif,
binds to purified and cellular calcineurin and competes
with GST-CNBR2 for binding to calcineurin. Retroviral
overexpression of Flag-Pep3 in the murine D10G4.1 TH2
cell line impaired the expression of IL-5, IL-6 and IL-13
and the nuclear translocation of NFATc3 after PMA/cal-
cium ionophore stimulation. NFATc3, but not NFATc2
and NF-κB activation is affected by Pep3 [182].
The  LxVPc1 peptide, spanning the 15 amino acids of
human NFATc1 371-385, disrupts calcineurin-NFATc1
and c2 binding. GST-LxVPc1 binds to calcineurin more
efficiently than any of the PxIxIT motifs of NFATc1 to c4.
The GST-LxVPc2 fusion peptide from NFATc2 was unable
to bind to calcineurin under the same conditions. The
LxVPc1 peptide inhibits calcineurin phosphatase activity
on the RII phosphopeptide and increases the phosphatase
activity on pNPP. Overexpression of GFP-LxVPc1 fusion
protein in HeLa cells inhibits NFATc2 dephosphorylation
and nuclear translocation upon ionophore treatment; in
Jurkat T cells it inhibits NFATc2 dephosphorylation and
the expression of luciferase under control of the IL-2 or
RCAN1-4 promoter upon PMA/ionophore stimulation
[23,24].
Protein fragments based on other motifs were derived
from CABIN1 and RCAN1. The protein fragment
CABIN1700-901 inhibits the dephosphorylation of the RII
phosphopeptide by calcineurin in a noncompetitive man-
ner. Overexpression of CABIN1700-901 in HEK293 cells
coexpressing constitutively active calcineurin inhibits the
dephosphorylation of NFATc2, its nuclear translocation
and luciferase reporter gene expression under NFAT con-
trol. Overexpression of this fragment in Jurkat T cells sup-
presses the expression of luciferase controlled by the IL-2
promoter upon PMA/ionomycin stimulation [183].
RCAN1 and 2 contain a SP repeat motif binding to the cat-
alytic centre of calcineurin. The SP repeat peptide
(RCAN1-495-118), which can be phosphorylated by MAPK
and GSK-3, simulates a substrate for calcineurin and
thereby inhibits calcineurin activity against RII  phos-
phopeptide in a competitive manner in cell-free assays.
This inhibitory effect is independent of the phosphoryla-
tion status of the peptide. However, overexpressed
RCAN1 fragments containing only the SP repeat domain
do not suppress calcineurin-NFATc signalling in cells
[184,185]. A peptide containing the CIC motif and the C-Cell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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terminal 30 amino acids of RCAN1 blocks dephosphor-
ylation of the RII phosphopeptide by calcineurin, but nei-
ther the CIC containing peptide nor the C-terminus alone.
It is suggested, that the C-terminal inhibitory motifs have
to be in close proximity to calcineurin via binding of the
CIC motif [179].
Pathogen proteins
Calcineurin represents a crucial hub of T cell receptor-
dependent signalling and controls the T cell activation
mainly via NFATc dephosphorylation. Targeting this
mechanism would enable pathogens to evade the host
immune responses. Therefore, several viruses and bacteria
have developed proteins inhibiting calcineurin-NFATc-
dependent signalling. Characterizing these proteins might
help to understand host defence mechanisms.
VacA is a protein from H. pylori, which inhibits the nuclear
translocation of NFATc. In addition, VacA blocks ionomy-
cin-induced increase of intracellular Ca2+ level, and the
activation of the MKK3/6-p38 MAPK pathway. These data
suggest multiple modes of VacA action, not all of them
seem to be calcineurin-NFATc-dependent [186]. How-
ever, VacA inhibits T cell activation, proliferation and IL-2
secretion in Jurkat cell lines and primary human CD4+ T
cells [187,188]. VacA is imported into the T cell via the
receptors CD18 and LFA-1 [189]. The expression of these
cell surface proteins varies in different cell types, resulting
in a different magnitude of inhibitory effects.
A238L, a protein of the african swine fever virus, seems to
have different functions: first, to bind to calcineurin and
inhibit its phosphatase activity and thus calcineurin-
dependent pathways [190]; second, to suppress the
acetylation and transcriptional activation of the transcrip-
tion factors NFATc2, NF-κB, and c-Jun by inhibition of
transactivation of the transcriptional co-activator CREB
binding protein/p300 by PKCθ in stimulated human T
cells [191]; and third, to inhibit the activation of JNK
[192]. Overexpression of A238L reduces calcineurin phos-
phatase activity against RII phosphopeptide in cell lysates
and diminishes NFATc-dependent reporter gene expres-
sion in transfected porcine RS-2 kidney cells [190]. It is
speculated that A238L only inhibits the dephosphoryla-
tion of such NFATc residues which might be crucial for its
transactivation function but has no effect on the dephos-
phorylation of the other residues required for nuclear
translocation or DNA binding [193]. Effects of A238L on
NFATc-dependent gene transcription are abolished by co-
overexpression of the constitutively active calcineurin
construct  ΔCaM-AI or NFATc2 in Jurkat T cells [193].
Interestingly, A238L binds also to CypA, but this interac-
tion seems to have no effect on A238L-calcineurin interac-
tion [190].
The fragment A238L157-238 contains a PxIxIT site (here:
PKIIITG) and binds to calcineurin with high affinity. The
14 mer oligopeptide derived from this fragment A238L200-
213 binds to calcineurin even with a faster rate than the
SPRIEIT peptide of porcine NFATc1 [194].
Commentary
Clinical application
CsA and FK506 as well as some of their derivatives have
become indispensible drugs to prevent transplant rejec-
tion and to treat dermatologic and autoimmune disor-
ders. However, these drugs have a narrow therapeutic
window. To reduce their adverse side effects different
approaches were tested and some of them are still under
investigation.
One strategy is to reduce the concentration of CsA and
FK506, respectively, by combined application together
with other immunosuppressive drugs having different
modes of action, such as mycophenolate, rapamycin or
monoclonal antibodies (e.g. Alemtuzumab). Another
approach, especially in atopic dermatitis is to diminish
systemic effects of the drugs by topical application of
derivatives with enhanced lipophilic properties, such as
pimecrolimus. A third approach is to apply CsA in low
doses, thus taking advantage not only of its immunosup-
pressive, but also of its immunomodulatory properties
[39].
Recently, some drugs originally introduced for applica-
tions other than inflammation turned out to act as inhib-
itors of calcineurin/NFATc activation. Among them are
barbiturates, tropisetron and the acetaminophen/para-
cetamol catabolite AM404.
Application in basic research
Small molecular inhibitors and inhibitory peptides are
valuable tools for a functional "knock-down" of cellular
components to study the impact of different proteins,
processes and pathways on specific cellular functions.
Ideal inhibitors have to be monospecific, cell permeable
and non-toxic. Most of the novel inhibitors, however, are
not as well characterized as the "classical" inhibitors CsA
and FK506.
Here we recommend the application of several inhibitors
in basic research based on the intended investigations
(Figure 2).
Inhibition of different Ser/Thr phosphatase activities
Norcantharidin inhibits PP1, PP2A and calcineurin with
comparable efficacy. Okadaic acid or calyculin A can be
used to discriminate between calcineurin and the other
main Ser/Thr protein phosphatases when applied in the
nanomolar concentration range. Under this conditionCell Communication and Signaling 2009, 7:25 http://www.biosignaling.com/content/7/1/25
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they inhibit PP1 and PP2A, which account for more than
90% of the cellular Ser/Thr phosphatase activity, and
additionally PP4, PP5 and PP6, but they fail to inhibit cal-
cineurin.
Inhibition of calcineurin phosphatase activity without modulation of 
PPIases activities
Gossypol and kaempferol are useful to inhibit the phos-
phatase activity of calcineurin not only in enzymatic
assays but also in primary cells due to their low cytotoxic-
ity. They inhibit calcineurin without the need for a match-
maker protein. Both compounds, however, additionally
inhibit several other cellular enzymes. Inhibitors of cal-
cium signalling, e.g. BTP2 and trifluoperazine, suppress
the activation of calcineurin but they also act on other
Ca2+- or calmodulin-dependent processes, such as Ca2+-
dependent PKCs or CaMKI/II. Peptides derived from the
auto-inhibitory domain of calcineurin inhibit the phos-
phatase activity with high specificity, but their application
is limited due to their reduced cell permeability.
Inhibition of NFATc dephosphorylation
NCI3 and dipyridamole are cell permeable compounds
which inhibit NFATc dephosphorylation in cells without
inhibition of the phosphatase activity of calcineurin in
enzymatic assays. INCA-6 inhibits NFATc dephosphoryla-
tion and can be used in cell-free systems but is not recom-
mended in primary cells due to its cytotoxicity. VIVIT
peptide competes with NFATc for binding to calcineurin
and is appropriate to inhibit NFATc dephosphorylation in
cell-free assays.
Inhibition of NFATc-dependent gene transcription
BTP1, ST1959 and Roc-1 inhibit NFATc-dependent gene
transcription presumably downstream of the calcineurin-
NFATc interaction. These compounds are supposed to
have no or low inhibitory effects on NF-κB or AP-1 activa-
tion.
Several other novel inhibitors of NFATc-dependent gene
transcription have been isolated or synthesized. However,
most of them have not been characterized so far and their
molecular mode of action remains to be elucidated.
Therefore, these compounds cannot be recommended as
tools to dissect and define mechanisms of calcineurin
action in the complex signalling network of cells.
Conclusion
In summary, CsA and FK506 are firmly established in the
clinical routine. Several approaches are applied or under
investigation to limit their side effects. In basic research,
several more specific, although less well characterized,
inhibitors of the calcineurin-NFATc axis can be utilized as
alternatives. So far, their widespread application is hin-
dered by a limited commercial availability.
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